Reports Q1 revenue $73.46M, consensus $71.26M. Ming Hsieh, chairperson of the board of directors and CEO, said, “I am pleased with the first quarter results and momentum we are seeing so far in 2025. Our Laboratory Services business is well-positioned for growth, and we continue to progress our Therapeutic Development pipeline.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FLGT: